Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1365-2141.2002.03663_2.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Molecular profiling of myeloid/natural killer (NK) cell precursor acute leukemia].
Rinsho Ketsueki
October 2024
Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU).
Article Synopsis
- Myeloid/natural killer (NK) cell precursor acute leukemia (MNKPL) is proposed as a unique leukemia type but lacks international consensus due to its rarity and unclear molecular features.
- Multi-omics analysis shows that MNKPL is different from other types of leukemia and reveals specific genetic markers, such as NOTCH1 and RUNX3 activation, along with BCL11B downregulation.
- A case study indicates poor patient outcomes even after treatment, but MNKPL cells are sensitive to the drug L-asparaginase, potentially improving treatment options.
Successful Cord Blood Transplantation for Myeloid/Natural Killer Precursor Acute Leukemia: A Case Report and Literature Review.
Intern Med
September 2024
Department of Hematology, Tohoku University Hospital, Japan.
A 21-year-old man was diagnosed with myeloid/natural killer precursor leukemia (MNKPL) with bone marrow infiltration of blasts of cyCD3, CD7, CD33, CD34, CD56, HLA-DR, cyMPO, and TdT immunophenotypes. Although hyper-CVAD therapy was unsuccessful, induction treatment with idarubicin and cytarabine resulted in complete remission (CR). The patient subsequently underwent cord blood transplantation with a myeloablative conditioning regimen, which resulted in durable CR and complete donor chimerism.
View Article and Find Full Text PDFMyeloid/natural killer (NK) cell precursor acute leukemia as a distinct leukemia type.
Sci Adv
December 2023
Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Article Synopsis
- * Multiomics analysis showed MNKPL is distinct from other leukemia types and suggested that both NK and myeloid cells may originate from shared progenitor cells.
- * Current treatments for MNKPL are not very effective, but the study found that MNKPL is especially sensitive to the drug l-asparaginase, which aligns with clinical observations of its effectiveness in patients.
Effectiveness of venetoclax and azacytidine against myeloid/natural killer cell precursor acute leukemia.
Int J Hematol
January 2024
Department of Hematology, Graduate School of Medicine, Osaka City University, 1-4-3, Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan.
Myeloid/natural killer (NK) cell precursor acute leukemia (MNKPL) is a rare leukemia subtype that possibly originates from precursor NK cells. The disease has a poor prognosis, and information on its treatment is lacking. We herein report the first case of a 46-year-old woman with MNKPL who was refractory to two lines of acute myeloid leukemia (AML)-type intensive chemotherapy but was successfully treated with venetoclax and azacytidine (VEN/AZA).
View Article and Find Full Text PDFImprovement of human myeloid and natural killer cell development in humanized mice via hydrodynamic injection of transposon plasmids containing multiple human cytokine genes.
Immunol Cell Biol
September 2022
Key Laboratory of Organ Regeneration & Transplantation of Ministry of Education, The First Hospital of Jilin University, Changchun, China.
Humanized mice reconstituted with a functional human immune system (HIS) are instrumental in studying human immunity and immune disorders in vivo. The poor or lack of cross-reactivity between mouse cytokines and human cells limits the development and/or function of human immune cell subsets including human myeloid, natural killer and B cells. Here we explored the potential to achieve long-term production of human cytokines in immunodeficient mice using a transposon-plasmid-based hydrodynamic injection approach.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!